EJC paediatric oncology最新文献

{"title":"Evaluation of the impact of adherence to infection prevention measures on the quality of life in children with hematologic malignancies","authors":"Dorine Poelmans ,&nbsp;Jaques van Heerden","doi":"10.1016/j.ejcped.2026.100482","DOIUrl":"10.1016/j.ejcped.2026.100482","url":null,"abstract":"<div><h3>Purpose</h3><div>The survival rate for paediatric hematological malignancies has improved significantly, shifting focus to Health Related Quality of Life (HRQOL). The objectives of this study was to investigate the impact of infection prevention lifestyle adjustments on HRQOL and to determine whether these adjustments were feasible and applicable in practice.</div></div><div><h3>Methodology</h3><div>A prospective quantitative cross-sectional study was done, in which 21 children between 6 and 18 years old, treated for an hematological malignancy at the University Hospital Antwerp were interviewed. The questionnaire was developed in accordance with PedsQL™, consisting of 27, five-point Likert scale questions.</div></div><div><h3>Results</h3><div>The impact of lifestyle modifications to avoid infections on the HRQOL was assessed using a physical, social, emotional and school domain, of which the median was 3.2 [IQR 2.6; 3.7], 3.5 [IQR 3; 4], 3.5 [IQR 2.9; 4.6] and 3.7 [IQR 3.3; 4.3] respectively. These corresponded to 'rarely to sometimes' having difficulty complying with these rules. The feasibility and applicability of complying in practice was tested in the physical, social and school domain, of which the median was 1.2 [IQR 1; 1.5], 1 [IQR 1; 1.5] and 1 [IQR 1; 1] respectively. These corresponded to 'always' being feasible and applicable.</div></div><div><h3>Conclusion</h3><div>The first study showed that HRQOL was impacted by lifestyle modifications to avoid infections and influenced in every domain, especially the physical domain. Although children and/or their proxy indicated that the guidelines were feasible and applicable in practice the evidence of these recommendations must be evaluated.</div></div>","PeriodicalId":94314,"journal":{"name":"EJC paediatric oncology","volume":"7 ","pages":"Article 100482"},"PeriodicalIF":0.0,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145978275","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pharmacokinetic variability of mitotane in pediatric adrenocortical carcinoma and the role of CYP2B6 genotypes: a pediatric case series","authors":"Ivy A.E. Ankone ,&nbsp;Tirsa de Kluis ,&nbsp;Lidwien M. Hanff ,&nbsp;Antoinette Jaspers-Bakker ,&nbsp;Ronald R. de Krijger ,&nbsp;Jesse J. Swen ,&nbsp;Kathalijne A. Oudhoff ,&nbsp;Marieke J.M. Meijs ,&nbsp;Max M. van Noesel ,&nbsp;Alwin D.R. Huitema ,&nbsp;Meta H.M. Diekstra","doi":"10.1016/j.ejcped.2026.100499","DOIUrl":"10.1016/j.ejcped.2026.100499","url":null,"abstract":"<div><div>Despite therapeutic drug monitoring of mitotane, achieving target plasma concentrations remains challenging. Commonly reported enzymes involved in mitotane metabolism are cytochrome P450 (CYP)3A4 and 2B6, with CYP2B6 being highly polymorphic. We evaluated the impact of <em>CYP2B6</em> genotypes on achieving therapeutic concentrations in six patients. We observed intermediate, normal, and rapid metabolizer genotypes. Intermediate or normal metabolizers all reached therapeutic concentrations, receiving between 3.5–5.5 g/m²/day. The rapid metabolizer did not reach therapeutic concentrations despite receiving up to 8.0 g/m²/day. These results indicate <em>CYP2B6</em> genotypes may affect the dose needed to achieve and maintain therapeutic concentrations of mitotane in pediatric adrenocortical carcinoma.</div></div>","PeriodicalId":94314,"journal":{"name":"EJC paediatric oncology","volume":"7 ","pages":"Article 100499"},"PeriodicalIF":0.0,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147384840","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Challenges in delineation for Ewing Sarcoma of the chest wall and pelvis: Results of a QUARTET – Euro-Ewing Consortium joint workshop","authors":"Maria Chiara Lo Greco ,&nbsp;Volha Hertsyk ,&nbsp;Melissa Christiaens ,&nbsp;Line Claude ,&nbsp;Coreen Corning ,&nbsp;Emma d’Ippolito ,&nbsp;Raquel Davila-Fajardo ,&nbsp;Karin Dieckmann ,&nbsp;Jacob Engellau ,&nbsp;Jenny Gains ,&nbsp;Daniela Greto ,&nbsp;Yi-Lan Lin ,&nbsp;Henriette Magelssen ,&nbsp;Henry Mandeville ,&nbsp;Valentine Martin ,&nbsp;Daiva Sendiuliene ,&nbsp;Beate Timmermann ,&nbsp;Andrada Turcas ,&nbsp;Lorna Zadravec Zaletel ,&nbsp;Sarah Kelly ,&nbsp;Akmal Safwat","doi":"10.1016/j.ejcped.2026.100522","DOIUrl":"10.1016/j.ejcped.2026.100522","url":null,"abstract":"<div><h3>Introduction</h3><div>Despite existing radiotherapy contouring guidelines for Ewing’s Sarcoma (ES), important gaps remain for certain anatomical sites. The Euro-Ewing Consortium radiotherapy committee collaborated with QUARTET to identify and address ambiguities through consensus statements.</div></div><div><h3>Material and methods</h3><div>Between September 2023 and March 2025, a series of delineation workshops were held using two previously treated cases: a pelvic ES treated with radical radiotherapy and a chest wall ES treated post-operatively. The requested structures included GTVp_Pre, GTVp_Post, CTVp_Pre_4500 and CTVp_Post_5400 for both cases; as well as CTVp_Post_6000 for pelvic case and CTVp_Lung_1500 for chest wall case. Visual and quantitative analyses were performed.</div></div><div><h3>Results</h3><div>For the pelvic case, substantial variability was observed in the CTVp_Pre_4500, CTVp_Post_5400, and CTVp_Post_6000 volumes. As differences were primarily related to adjustments at anatomical barriers, participants agreed to consider compartmental fascia as natural barriers in the absence of infiltration, and to apply a 0.5-cm margin beyond the barrier when the ES is in direct contact. For the chest wall case, variability in GTVp_Pre and GTVp_Post were related to changes between pre- and post-operative anatomy and reflected in CTVp_Pre_4500 and CTVp_Post_5400 delineation. It was therefore agreed that non-infiltrated surfaces in contact with the tumour before surgery should be included in the GTVp_Pre. Standard margins should be applied to generate CTVp_Pre_4500, which should then be edited to avoid the skin, lungs, and heart while ensuring inclusion of the surgical bed.</div></div><div><h3>Conclusions</h3><div>The delineation workshops highlighted significant inter-clinician variability in target definition for ES. The resulting consensus statements will be used to supplement existing resources and support clinicians.</div></div>","PeriodicalId":94314,"journal":{"name":"EJC paediatric oncology","volume":"7 ","pages":"Article 100522"},"PeriodicalIF":0.0,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148167370","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Stereotactic ablative radiotherapy extends time to subsequent systemic therapy in pediatric cancer patients with recurrent or metastatic disease","authors":"Sean P. Hassan ,&nbsp;Nisha Shariff ,&nbsp;Xuan Li ,&nbsp;Yuan Zhong ,&nbsp;Alejandro Shiri Moreno ,&nbsp;Dana M. Keilty ,&nbsp;David C. Hodgson ,&nbsp;Paul C. Nathan ,&nbsp;Furqan Shaikh ,&nbsp;Anita Villani ,&nbsp;David Malkin ,&nbsp;Avram Denburg ,&nbsp;Kriti Kumar ,&nbsp;Derek S. Tsang","doi":"10.1016/j.ejcped.2026.100526","DOIUrl":"10.1016/j.ejcped.2026.100526","url":null,"abstract":"<div><h3>Background and Aims</h3><div>Stereotactic ablative radiotherapy (SAbR) has been used in the adult population for decades, providing local control (LC) and, in some cases, overall survival (OS) advantage. It can also extend the time to subsequent systemic therapy, reducing side effect burden and improving quality of life. This retrospective study aimed to evaluate the effectiveness of SAbR in prolonging time to subsequent systemic therapy in children.</div></div><div><h3>Methods</h3><div>We performed a single-institution retrospective analysis of children who underwent extracranial SAbR over 2 – 5 fractions (dose per fraction &gt; 5 Gray [Gy]) for recurrent or progressive cancer between 2009 and 2024. The primary endpoint was time from SAbR to next use of systemic therapy. Secondary endpoints included LC and OS, as well as the impact of biological effective dose (BED) and equivalent dose in 2-Gy fractions (EQD2) thereon.</div></div><div><h3>Results</h3><div>Thirty-five pediatric patients with cancer had 97 lesions that received at least one course of SAbR meeting minimum dose criteria (BED10 ≥30 Gy). The cumulative incidence of any systemic therapy change at 12 months was 0.58 (95% CI 0.47–0.68). The cumulative incidence of IV systemic therapy change at 12 months was 0.36 (95% CI 0.26–0.47), with a median time to IV systemic therapy change of 11.9 months. Risk of local progression was associated with non-sarcoma histology compared with soft tissue sarcoma (Hazard Ratio [HR] 4.19; 95% Confidence Interval [CI] 1.25–14.06; p = 0.021). Median OS from first SAbR was 12.8 months (95% CI 7.82–26.20). There was no statistically significant association of LC with BED or EQD2.</div></div><div><h3>Conclusions</h3><div>In this single-institution case series, SAbR was associated with a delay to subsequent IV systemic therapy change in pediatric cancer patients and may serve as a means to manage disease progression while minimizing burden of therapy. Prospective studies are needed to confirm these findings.</div></div>","PeriodicalId":94314,"journal":{"name":"EJC paediatric oncology","volume":"7 ","pages":"Article 100526"},"PeriodicalIF":0.0,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148167372","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Chronic fatigue among adult, long-term survivors of childhood cancer compared to the general population: The Nor-CAYACS study","authors":"Christina Signorelli ,&nbsp;Corina S. Rueegg ,&nbsp;Cecile E. Kiserud ,&nbsp;Sara Hassing Johansen ,&nbsp;Hanne C. Lie","doi":"10.1016/j.ejcped.2026.100527","DOIUrl":"10.1016/j.ejcped.2026.100527","url":null,"abstract":"<div><h3>Introduction</h3><div>Fatigue is common, yet poorly understood in childhood cancer survivors, hampering effective long-term management. We aimed to compare fatigue in adult survivors of childhood cancer with the general population; and identify potentially modifiable associated factors.</div></div><div><h3>Methods</h3><div>Inclusion: childhood cancer survivors from the population-based NOR-CAYACS study (except survivors of central nervous system tumors) diagnosed 1985–2000. Normative data were available from a separate population-based study weighted according to current age and sex distribution. We assessed chronic fatigue and severity (Chalder’s Fatigue Questionnaire; score ≥4) and compared chronic fatigue occurrence (total score), and fatigue duration (≥6months), in survivors and the general population using linear regression and chi-squared tests. Multivariable linear regressions with blockwise variable addition based on a directed acyclic graph identified associated modifiable factors of fatigue severity.</div></div><div><h3>Results</h3><div>583 survivors (57% female, mean=19.1years post-diagnosis, 34% response) and 642 from the general population (35% response) were included. Significantly more survivors reported chronic fatigue than the general population (score ≥4; 25% vs 17%, <em>p = 0.022</em>), greater fatigue severity and symptom duration (≥6months, 53% vs 39%, p &lt; 0.001). Less fatigue severity was associated with male, not female, sex (<em>β</em>=−1.4, 95<em>%</em>CI=−2.4 to −0.5, <em>p = 0.002</em>) and a university, not no university, degree (<em>β</em>=−1.2, 95<em>%</em>CI=−2.1 to −0.2, <em>p = 0.015</em>). Higher fatigue severity was associated with ≥ 1 self-reported late-effects (versus none), (<em>β</em>=2.6, 95%CI<em>=</em>1.6–3.6, <em>p &lt; 0.001</em>), more hours of daily sleep (<em>β</em>=0.5, 95%CI=0.2–0.9, <em>p = 0.002</em>), greater pain interference (versus none/little) (<em>β</em>=3.9, 95%CI=2.7–5.1, <em>p &lt; 0.001</em>), and higher depressive symptoms (<em>β</em>=0.7, 95%CI=0.6–0.8, <em>p &lt; 0.001</em>) in the multivariable model, explaining 52% of variance.</div></div><div><h3>Conclusions</h3><div>Survivors reported chronic fatigue more often than the general population. Fatigue severity was associated with modifiable factors that may be targeted to mitigate the impact of fatigue on survivors’ well-being.</div></div>","PeriodicalId":94314,"journal":{"name":"EJC paediatric oncology","volume":"7 ","pages":"Article 100527"},"PeriodicalIF":0.0,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148167373","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pain management during interventions in paediatric oncology in Europe – Results from a pan-European survey","authors":"Eva-Maria Wild ,&nbsp;Gianluca Piccolo ,&nbsp;Eleni Syrimi ,&nbsp;Rahel Kasteler ,&nbsp;Bob Philips ,&nbsp;Gilles Vassal ,&nbsp;Ciara Sheehan ,&nbsp;Lejla Kameric ,&nbsp;Theodora Armenkova ,&nbsp;Katrin Scheinemann ,&nbsp;Maria Otth","doi":"10.1016/j.ejcped.2025.100481","DOIUrl":"10.1016/j.ejcped.2025.100481","url":null,"abstract":"<div><h3>Background</h3><div>Childhood cancer survival rates have improved over the last decades. Nevertheless, childhood cancer treatment is associated with painful interventions needed for disease monitoring or treatment. It is therefore crucial to ensure appropriate pain control for painful interventions. This European survey aims to map the approaches to manage such interventions in children and adolescents with cancer.</div></div><div><h3>Methods</h3><div>An online survey was sent to members of the European Society of Paediatric Oncology, asking the way potentially painful interventions are being managed. Interventions included lumbar puncture, bone marrow aspiration and biopsy, removal of drainages, insertion and removal of central venous lines, puncture of porth-a-cath or Ommaya reservoir, tumour biopsy, and insertion of nasogastric tube. Proposed approaches to pain management included local analgesia, systemic analgesia alone, systemic analgesia with sedation administrated by paediatric oncologists or anaesthesiologists, distraction techniques, and other methods. We further asked about drugs used and types of distraction.</div></div><div><h3>Results</h3><div>A total of 326 health care professionals responded, representing 37 countries. The proportion of participants reporting that an intervention is performed without any pain management ranged from one participant each for bone marrow aspiration/biopsy and tumor biopsy (0,3 %), to 101 participants (31 %) for nasogastric tube insertion. The intensity of analgesia or depth of sedation per intervention is heterogeneous, so are the drugs used.</div></div><div><h3>Conclusion</h3><div>The heterogenous results in use of analgesia or sedation during procedures indicate an unmet need. These results highlight the need for guidelines and their implementation in clinical practice. No child or adolescent undergoing cancer treatment should suffer from procedure-related pain.</div></div>","PeriodicalId":94314,"journal":{"name":"EJC paediatric oncology","volume":"7 ","pages":"Article 100481"},"PeriodicalIF":0.0,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145765800","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Making shared care work: A national qualitative case study on collaborative practice in pediatric oncology","authors":"Natasja Dors ,&nbsp;Martine van Grotel ,&nbsp;Eline Zijtregtop ,&nbsp;Nathalie van der Salm ,&nbsp;Laura Keukens ,&nbsp;Selma Lavrijssen ,&nbsp;Charlotte Drykoningen ,&nbsp;Anne Jonge Poerink ,&nbsp;Rod Thompson ,&nbsp;Jenneke Homan ,&nbsp;Menco Weismuller ,&nbsp;Wendy Nix ,&nbsp;Hester Blufpand ,&nbsp;Annemieke van der Wey ,&nbsp;Daniëlle Martens ,&nbsp;Marion Hekkelaan ,&nbsp;Lotte Helder ,&nbsp;Wouter Kollen ,&nbsp;Max van Noesel ,&nbsp;Marije P. Hennus","doi":"10.1016/j.ejcped.2026.100485","DOIUrl":"10.1016/j.ejcped.2026.100485","url":null,"abstract":"<div><h3>Background</h3><div>In 2018, the Netherlands centralized all pediatric oncology care at the Prinses Máxima Center (Máxima), supported by a national network of 14 Shared Care centers. These centers deliver non-intensive treatment and supportive care closer to home, enabling a hybrid model of centralized expertise and regional accessibility. While structurally in place, little is known about how regional pediatricians experience this collaboration or which factors they consider essential to its success.</div></div><div><h3>Methods</h3><div>This national qualitative multiple case study explored interprofessional collaboration between the Máxima and its Shared Care partners, from the perspective of pediatricians in all 14 regional centers. Semi-structured interviews were conducted, transcribed, and analyzed inductively using ATLAS.ti. Analysis was informed by Kaats &amp; Opheij’s collaboration framework, encompassing shared ambition, mutual interests, interpersonal relationships, structured collaboration, and meaningful processes. Peer debriefing was used to enhance trustworthiness and ensure clinical relevance.</div></div><div><h3>Results</h3><div>Participants emphasized that close collaboration is indispensable for delivering safe, high-quality pediatric oncology care. Enabling factors included mutual trust, personal familiarity, timely and clear communication, and professional recognition. Challenges were identified in areas such as inconsistent policy implementation, opaque decision-making, and insufficient acknowledgment of local expertise. Many called for differentiated, context-sensitive care agreements rather than one-size-fits-all approaches.</div></div><div><h3>Conclusion</h3><div>Effective shared care requires more than structural alignment: it demands investment in professional relationships, shared goals, and adaptive processes. These findings offer actionable insights to improve collaboration within the Dutch model and provide transferable lessons for other countries navigating centralized care in highcomplex, low-volume pediatric specialties.</div></div>","PeriodicalId":94314,"journal":{"name":"EJC paediatric oncology","volume":"7 ","pages":"Article 100485"},"PeriodicalIF":0.0,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146023598","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Congenital histiocytosis with central nervous system involvement and a novel PTPRJ::RASGRF1 fusion","authors":"Paul G. Kemps ,&nbsp;Marianna Bugiani ,&nbsp;Marijn A. Scheijde-Vermeulen ,&nbsp;Marco J. Koudijs ,&nbsp;Jean-François Emile ,&nbsp;Olvert A. Berkhemer ,&nbsp;Wes Onland ,&nbsp;Cor van den Bos","doi":"10.1016/j.ejcped.2026.100492","DOIUrl":"10.1016/j.ejcped.2026.100492","url":null,"abstract":"<div><div>Histiocytic neoplasms are rare diseases characterized by clonal expansions of cells with a macrophage or dendritic cell phenotype. They are driven by mutations activating the MAPK pathway and may involve diverse organs, including the central nervous system (CNS). We describe a newborn with congenital histiocytosis affecting the CNS, skin, lungs, lymph nodes, thyroid, fingernail, and soft tissues – including a tumor originating from the tongue obstructing the upper airway. Histopathology revealed an atypical histiocytosis with strong CD1a and variable Langerin expression; post-mortem transcriptome sequencing identified a novel <em>PTPRJ::RASGRF1</em> fusion. This case expands the molecular landscape of histiocytic neoplasms, highlighting the value of comprehensive genomic profiling.</div></div>","PeriodicalId":94314,"journal":{"name":"EJC paediatric oncology","volume":"7 ","pages":"Article 100492"},"PeriodicalIF":0.0,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147384836","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Experiences of receiving explanations about medical conditions among adolescent children with cancer: A qualitative study","authors":"Yuta Kogumazaka ,&nbsp;Takako Miyamura ,&nbsp;Tae Kawahara ,&nbsp;Tomoko Abe ,&nbsp;Saaya Niino ,&nbsp;Akemi Yamazaki","doi":"10.1016/j.ejcped.2026.100486","DOIUrl":"10.1016/j.ejcped.2026.100486","url":null,"abstract":"<div><h3>Background</h3><div>Although international consensus has been reached on the implementation of open communication for children with cancer, few studies have captured the reality of their experiences of receiving explanations of their medical conditions. This study aimed to investigate the experiences of patients diagnosed with cancer during adolescence in terms of receiving explanations of their medical conditions from health-care professionals and parents, and to identify the trajectory of how adolescent children with cancer approach their treatment after receiving explanations.</div></div><div><h3>Methods</h3><div>Semi-structured interviews were conducted on 18 childhood cancer survivors who completed treatment between May 2024 and June 2025. The inclusion criteria included having been diagnosed with cancer between the ages of 11 and 18 years and having received an explanation of their condition. The grounded theory approach was used for the data analysis, which included a verbatim record and theoretical notes.</div></div><div><h3>Results</h3><div>Five categories were identified as Experiences of receiving explanations about medical conditions among adolescent children with cancer: “Receiving explanations of my medical condition”, “Mixed feelings”, “Concerns during hospitalization”, “I’ve got cancer”, and “The power to overcome treatment”.</div></div><div><h3>Conclusions</h3><div>The present findings suggest the need to provide psychological support during the process of explaining medical conditions to children. Furthermore, the concerns of children need to be captured in daily interactions, and practices that help them become aware of their disease and complete their treatment need to be developed.</div></div>","PeriodicalId":94314,"journal":{"name":"EJC paediatric oncology","volume":"7 ","pages":"Article 100486"},"PeriodicalIF":0.0,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146023597","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"High-grade/large B-cell lymphoma with 11q aberration: A distinct molecularly defined entity in contemporary pathobiological classifications","authors":"Matej Jelić ,&nbsp;Madalina Bota ,&nbsp;Ingrid Simonitsch-Klupp ,&nbsp;G.A. Amos Burke ,&nbsp;Andishe Attarbaschi","doi":"10.1016/j.ejcped.2026.100494","DOIUrl":"10.1016/j.ejcped.2026.100494","url":null,"abstract":"<div><h3>Purpose</h3><div>High-grade/large B-cell lymphoma with 11q aberration (HGBCL-11q) is an aggressive mature B-cell lymphoma that mimics Burkitt lymphoma (BL) but lacks <em>MYC</em>-rearrangements. Correct diagnosis is essential to avoid misclassification and to support (future) risk-adapted management.</div></div><div><h3>Methods</h3><div>We reviewed recent classification updates, pivotal clinicopathologic reports, and genomic studies addressing HGBCL-11q. Accordingly, we summarized diagnostic criteria including histomorphology, immunophenotype and genomics, and collate reported clinical characteristics and treatment outcomes.</div></div><div><h3>Results</h3><div>HGBCL-11q is characterized by a chromosome 11q copy-number profile with a proximal gain/amplification at 11q23.2–q23.3 and a distal loss at 11q24.1–qter. Tumours typically show a germinal centre B-cell immunophenotype and BL-like histomorphology, yet genome-wide profiling supports assignment within the large B-cell lymphoma (LBCL) spectrum rather than true BL. HGBCL-11q predominantly affects children and adolescents and often presents with localized nodal disease in the head-and-neck region. In the largest multinational cohort of 72 pediatric patients, 3-year event-free and overall survival were 94 % and 96 %, respectively, with inferior outcomes mainly confined to patients with inborn and acquired errors of immunity or cancer predisposition syndromes.</div></div><div><h3>Conclusion</h3><div>HGBCL-11q is a genetically defined non-Hodgkin lymphoma with an excellent lymphoma-related prognosis under pediatric mature B-cell lymphoma–type regimens. Standardized testing for 11q aberration in cases of diffuse LBCL, HGBCL or BL morphology lacking <em>MYC</em>-rearrangements improves classification consistency and may enable chemoimmunotherapy de-escalation trials. Systematic evaluation for immunodeficiency and cancer predisposition syndromes is recommended to identify patients at risk and guide adapted therapy, supportive care and follow-up.</div></div>","PeriodicalId":94314,"journal":{"name":"EJC paediatric oncology","volume":"7 ","pages":"Article 100494"},"PeriodicalIF":0.0,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147384842","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}